List of Excipients in Branded Drug ORTIKOS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ferring Pharmaceuticals Inc	ORTIKOS	budesonide	55566-1002	ACETYLTRIBUTYL CITRATE
Ferring Pharmaceuticals Inc	ORTIKOS	budesonide	55566-1002	DIMETHICONE
Ferring Pharmaceuticals Inc	ORTIKOS	budesonide	55566-1002	ETHYLCELLULOSE
Ferring Pharmaceuticals Inc	ORTIKOS	budesonide	55566-1002	FERRIC OXIDE RED
Ferring Pharmaceuticals Inc	ORTIKOS	budesonide	55566-1002	FERRIC OXIDE YELLOW

ORTIKOS Excipient Strategy and Commercial Opportunities in Budesonide Extended-Release Capsules

Last updated: September 7, 2026

ORTIKOS is an oral budesonide extended-release capsule for induction of remission in adults with active mild-to-moderate Crohn's disease involving the ileum and/or ascending colon. Its commercial value depends on reliable multiparticulate release, protection of budesonide from gastric exposure, reproducible delivery to the distal small intestine and colon, and cost-efficient control of excipient and coating variability.

The strongest excipient opportunities are in enteric-coating systems, pellet processing, moisture control, capsule-shell optimization, and differentiated low-cost manufacturing. The principal commercial risks are generic substitution, limited differentiation from other budesonide products, formulation-equivalence requirements, and dependence on complex release testing rather than on the active ingredient alone.

What is ORTIKOS and how does its formulation work?

ORTIKOS contains budesonide in extended-release capsules at 6 mg and 9 mg strengths. The dosage form uses coated particles or pellets designed to delay drug release until the formulation reaches the intestinal region targeted for Crohn's disease treatment. FDA labeling identifies the product as an oral extended-release capsule rather than an immediate-release budesonide product. [1]

Budesonide has extensive first-pass hepatic metabolism. That pharmacology supports local gastrointestinal activity while limiting systemic exposure relative to nonselective corticosteroids, although systemic corticosteroid effects remain clinically relevant. [1,2]

The formulation must control four variables:

1. Gastric resistance.
2. Release onset at the intended intestinal pH.
3. Drug diffusion and dissolution after coating rupture or dissolution.
4. Capsule and pellet stability during storage and handling.

The dosage form is therefore more technically demanding than a conventional hard-gelatin capsule containing uncoated powder.

What excipients are used in ORTIKOS?

Public labeling identifies excipients associated with the capsule shell, pellet matrix, coating layers and processing system. The exact role of each material can vary by formulation layer and strength.

Excipient category	Typical function in ORTIKOS-type budesonide capsules	Commercial significance
Enteric polymers	Delay release in gastric fluid and trigger release at higher intestinal pH	Core performance driver
Ethylcellulose or similar water-insoluble polymers	Control diffusion and provide sustained release	Controls release rate and batch variability
Methacrylic acid copolymers	Provide pH-dependent intestinal release	Important for site-specific delivery
Povidone or other binders	Bind budesonide to starter cores or support pellet formation	Affects content uniformity
Polysorbate 80	Wetting or coating aid	Can improve coating uniformity but requires impurity and compatibility control
Talc	Anti-tacking and coating-process aid	Reduces agglomeration during fluid-bed coating
Triethyl citrate or related plasticizers	Improve polymer-film flexibility	Reduces cracking and improves storage stability
Magnesium stearate	Lubricant	Excessive levels can slow wetting or dissolution
Lactose or other diluents	Bulking or processing support	May create intolerance, moisture and supplier-control issues
Gelatin or HPMC	Capsule shell material	Supports capsule manufacture and brand presentation
Titanium dioxide and colorants	Capsule identification and appearance	Relevant to regulatory change control

The principal excipient strategy is not to replace every listed material. It is to identify which materials control critical quality attributes and which can be substituted without changing the product's release profile.

What formulation characteristics create the main commercial opportunity?

The most valuable formulation feature is the multiparticulate release system. A capsule can contain multiple pellets, allowing the manufacturer to distribute drug across many release units. This can reduce the effect of localized coating defects compared with a single-unit tablet.

Three formulation architectures are commercially relevant.

Enteric-coated budesonide pellets

Pellets may use a drug-containing core, a seal coat, a rate-controlling layer and an enteric layer. This architecture allows independent adjustment of drug loading, intestinal release threshold and release duration.

Commercial advantages include:

• Better control of dose uniformity.
• Flexible use of different pellet sizes.
• Potentially lower sensitivity to individual coating defects.
• Compatibility with standard hard-capsule filling equipment.

The disadvantages are higher process complexity, greater coating-material consumption and more extensive dissolution testing.

Drug-layered starter cores

Budesonide can be layered onto inert starter spheres using a binder solution or suspension. This approach can produce uniform drug distribution if spray rate, atomization, drying and bed temperature are controlled.

The main risks are:

• Agglomeration.
• Uneven drug loading.
• Budesonide migration during drying.
• Variability in pellet size and coating thickness.

A commercial improvement would be a higher-drug-load pellet that reduces excipient mass and coating time while maintaining content uniformity.

Alternative capsule-shell systems

A manufacturer could evaluate HPMC capsules instead of gelatin. HPMC may offer advantages in moisture control, vegetarian positioning and reduced cross-linking risk. The change would require capsule compatibility, dissolution, stability and bioequivalence assessment.

HPMC is not automatically superior. It can alter fill behavior, shell moisture and disintegration. For ORTIKOS, the capsule shell is part of the delivery system and should be treated as a critical material rather than as a simple packaging component.

Which excipient substitutions could reduce manufacturing cost?

The highest-value substitutions are likely to involve coating polymers, plasticizers, lubricants and capsule shells.

Target	Potential substitution strategy	Main regulatory and technical risk
Enteric polymer	Dual-source methacrylic acid copolymer with equivalent functionality	Different dissolution threshold or film permeability
Plasticizer	Triethyl citrate versus another approved citrate or phthalate-free plasticizer	Film flexibility, extractables and stability
Binder	Povidone grade optimization or alternative hydrophilic binder	Pellet strength and drug-layer uniformity
Capsule shell	Gelatin to HPMC	Shell dissolution, moisture and bioequivalence
Anti-tacking agent	Talc grade or concentration optimization	Coating defects and elemental impurity control
Lubricant	Magnesium stearate grade optimization	Wetting and dissolution changes
Diluent	Lactose reduction or replacement	Density, fill weight and content uniformity

A dual-source strategy should prioritize excipients with established pharmaceutical supply chains. The objective is not simply a lower unit price. A second qualified source can reduce shortage risk, improve negotiating leverage and support continuity after supplier changes.

How can ORTIKOS excipients support product differentiation?

Budesonide extended-release products are difficult to differentiate through the active ingredient. Differentiation is more credible when tied to measurable patient or manufacturing outcomes.

Lower capsule burden

A higher drug-load pellet could support a smaller fill mass or a lower number of capsules per dose. Any capsule-count reduction would need to preserve the labeled 6 mg and 9 mg strengths and demonstrate equivalent performance.

Improved moisture stability

Budesonide pellet systems can be sensitive to coating integrity and moisture migration. A lower-moisture capsule shell, improved barrier packaging or optimized seal coat could extend stability or simplify distribution in humid markets.

Reduced variability after food administration

Food can influence gastrointestinal transit, fluid exposure and dissolution. A formulation designed to minimize food-related variability could have commercial value, but this would require direct pharmacokinetic and clinical evaluation.

Improved swallowing characteristics

A smaller capsule, smoother shell and optimized capsule dimensions could improve administration. These changes may support lifecycle management, although they would not necessarily create strong patent protection.

Allergen and excipient positioning

Removal or reduction of lactose, gelatin, dyes or specific surfactants may support targeted patient and prescriber positioning. Such claims require accurate labeling and cannot imply clinical superiority without evidence.

What manufacturing and intellectual-property barriers affect ORTIKOS?

The main barrier is formulation equivalence. A competitor cannot generally rely on the same regulatory pathway as a simple immediate-release capsule because the release mechanism is central to product performance.

The critical manufacturing operations are:

• Drug layering or pellet formation.
• Fluid-bed drying.
• Polymer coating.
• Plasticizer incorporation.
• Capsule filling.
• In-process particle-size control.
• Multi-stage dissolution testing.
• Moisture and residual-solvent control.

Potential intellectual-property positions include claims directed to:

• Budesonide particle or pellet architecture.
• Specific coating-layer sequences.
• pH-dependent release profiles.
• Excipients used in defined concentration ranges.
• Capsule contents with specified dissolution behavior.
• Manufacturing processes for drug-layered pellets.
• Treatment of ileal or colonic inflammatory disease using a defined release profile.

Patent risk must be separated from regulatory exclusivity. The FDA Orange Book records patents and regulatory exclusivities associated with approved drug products, but the presence or absence of an Orange Book listing does not resolve every formulation or process dispute. [3]

For ORTIKOS, a serious freedom-to-operate review should cover U.S. patents, continuation applications, European patents, national-phase filings and expired legacy patents associated with budesonide controlled-release systems. A formulation may remain commercially differentiated even after core patents expire if it is difficult to reproduce consistently or if the sponsor has a regulatory advantage.

What is the FDA regulatory status and Orange Book significance?

ORTIKOS was approved as a prescription budesonide extended-release capsule for Crohn's disease. FDA labeling is the primary public source for dosage form, strength, indication, administration and inactive ingredients. [1]

The relevant regulatory issues are:

• Whether the product is approved under an NDA or an abbreviated pathway.
• Whether an approved generic has demonstrated equivalent release and exposure.
• Whether any patents or exclusivities are listed for the specific product.
• Whether formulation changes require a supplement, prior approval supplement or new clinical evidence.
• Whether excipient changes alter dissolution or bioequivalence requirements.

For a commercial developer, Orange Book review should be performed by product strength and application number. Patent listings should be compared against the actual proposed product and not treated as a complete substitute for a broader patent search. [3]

How strong is the commercial opportunity for excipient suppliers?

Excipient suppliers have four practical opportunities.

Qualified alternative sourcing

Suppliers can offer equivalent grades of enteric polymer, plasticizer, talc, binder and capsule-shell materials. The strongest value proposition is supported by comparative release data, regulatory documentation and global supply capacity.

Coating-system packages

A ready-to-use coating system can reduce development time by combining polymer, plasticizer and anti-tacking components. The supplier can provide process windows for spray rate, inlet temperature, atomization and curing.

High-performance capsule shells

Moisture-controlled gelatin or HPMC shells may support improved stability and differentiated packaging. The supplier must provide low variability in dimensions, moisture, mechanical strength and dissolution.

Analytical and regulatory support

Excipient vendors can increase switching probability by providing:

• DMF support.
• Nitrosamine and elemental-impurity assessments.
• Extractables and leachables data.
• Residual-solvent profiles.
• Compendial compliance documentation.
• Stability data.
• Change-notification commitments.

The highest-margin opportunity is usually an integrated formulation and process package rather than a commodity excipient sold independently.

How does ORTIKOS compare with other budesonide products?

Product type	Release objective	Excipient opportunity	Competitive issue
ORTIKOS extended-release capsule	Ileal and ascending-colon delivery for Crohn's disease	Pellet coating, capsule shell and moisture control	Generic substitution and limited active-ingredient differentiation
Enteric-coated budesonide capsule	Delayed intestinal release	Enteric-polymer optimization	Similar release technology
Budesonide MMX tablet	Colonic delivery for ulcerative colitis	Tablet matrix and MMX coating	Different dosage form and disease positioning
Immediate-release budesonide product	Rapid systemic or local exposure depending on product	Conventional tablet or capsule excipients	Not directly interchangeable with ORTIKOS

Budesonide products should not be treated as therapeutically interchangeable solely because they contain the same active ingredient. Release site, dosage form, indication and pharmacokinetics differ. [1,2]

What generic entry risks exist for ORTIKOS?

Generic entry can occur through a product that matches the reference drug's strength, dosage form, route and release behavior. The key risk factors are:

• Availability of validated pellet-coating technology.
• Access to qualified enteric polymers.
• Ability to reproduce dissolution across pH stages.
• Bioequivalence performance.
• Freedom to operate around formulation and process claims.
• Manufacturing scale and batch-to-batch consistency.

The highest-risk scenario is a generic manufacturer with an established multiparticulate platform and existing budesonide manufacturing capability. Commercial erosion may begin with one strength, particularly the higher-volume 9 mg presentation, before expanding to the full product line.

What licensing opportunities exist for ORTIKOS excipient technology?

Potential licensing structures include:

1. A coating-system license covering polymer blends and process parameters.
2. A CDMO agreement combining formulation development, scale-up and commercial manufacture.
3. A capsule-shell supply agreement with minimum-volume commitments.
4. A regional license for a modified-release budesonide platform.
5. A lifecycle-management agreement covering reduced capsule size, lower moisture sensitivity or alternative excipient composition.

The most defensible licensing package would combine formulation know-how, analytical methods, process controls and regulatory documentation. A single excipient composition is easier to design around than a complete development and manufacturing platform.

Key Takeaways

• ORTIKOS depends on multiparticulate budesonide release rather than on the active ingredient alone.
• Enteric polymers, rate-controlling polymers, plasticizers and capsule shells are the most commercially important excipient classes.
• The best cost-reduction opportunities involve dual sourcing, coating-process optimization and higher drug-load pellets.
• HPMC capsules, lower-moisture systems and lactose-reduced formulations offer potential lifecycle-management paths.
• Generic entry risk is driven by reproducible dissolution and bioequivalence performance.
• Excipient suppliers can capture greater value by offering complete coating systems, regulatory support and process parameters.
• Orange Book review is necessary but does not replace a full formulation, process and geographic patent analysis.
• The strongest commercial proposition is an integrated excipient and manufacturing platform, not a commodity material.

FAQs

Can ORTIKOS use a different enteric polymer?

A different enteric polymer may be feasible, but the replacement must preserve gastric resistance, intestinal release timing, dissolution behavior and bioequivalence. The change may require regulatory comparability and stability data.

Is HPMC a viable alternative to gelatin for ORTIKOS capsules?

HPMC may be viable where moisture control, vegetarian positioning or gelatin supply risk is important. The change requires evaluation of shell dissolution, fill compatibility, moisture migration and release performance.

Which excipient most affects ORTIKOS release?

The enteric polymer system generally has the greatest effect on release onset. Polymer grade, plasticizer level, coating thickness and curing conditions can materially change dissolution.

Can a lower-cost ORTIKOS formulation avoid pellet technology?

Avoiding multiparticulate technology would create substantial development risk because the release profile is central to the product's clinical and regulatory identity. A simplified dosage form would require strong comparative evidence.

Are budesonide extended-release products interchangeable?

No. Products containing budesonide may differ in release site, dosage form, indication and pharmacokinetics. Interchangeability depends on regulatory approval and product-specific evidence.

References

1. U.S. Food and Drug Administration. (n.d.). ORTIKOS (budesonide) extended-release capsules prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Budesonide drug products: labeling and clinical pharmacology information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Washington, DC: U.S. Department of Health and Human Services.